Home › Acute Myeloid Leukemia › Alabama
Acute Myeloid Leukemia clinical trials in Alabama
21 studies for Acute Myeloid Leukemia are looking for participants at sites in Alabama.
Cities in Alabama
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT05554406HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Nov 6, 2026 · NCT07145411A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05564390CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- University of Alabama O'Neal Cancer Center, Birmingham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05143996Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Alabama at Birmingham Cancer Center, Birmingham
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Oct 28, 2026 · NCT05554393A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Children's Hospital of Alabama, Birmingham
RecruitingPhase 1
Up to age 21 · All sexes · Updated Oct 23, 2026 · NCT07012044A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- University of Alabama - Birmingham, Birmingham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06824168Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Children's Hospital of Alabama, Birmingham
RecruitingPhase 3
Ages 1 to 25 · All sexes · Updated Sep 4, 2026 · NCT07022678Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University of Alabama Birmingham, Birmingham
RecruitingPhase 2/3
Ages 18 to 80 · All sexes · Updated Aug 5, 2026 · NCT06788756A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
Recruiting
Ages 60 and older · All sexes · Updated Jul 6, 2026 · NCT06697600A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Alabama at Birmingham, Birmingham
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Alabama Birmingham, Birmingham
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Mar 4, 2026 · NCT07044544Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- The Kirklin Clinic of UAB Hospital, Birmingham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 26, 2025 · NCT03850574Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- University of Alabama - Birmingham, Birmingham
RecruitingHealthy volunteers welcome
Ages 18 to 120 · All sexes · Updated Jul 25, 2025 · NCT05237258Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT06034275From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.